Please login to the form below

Huntington's disease

This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.

Teva’s weak pipeline hit by Tourette’s drug trial failure

Deutetrabenazine is already approved as Austedo for the treatment of movement disorder chorea in patients with Huntington’s disease and for tardive dyskinesia – a side effect of antipsychotic drugs – but Teva ... 110 and Otsuka’s

Latest news

Troubled Alkermes eyes November OK for new antipsychotic

The increased weight not only heightens patients’ risk of cardiovascular disease, but also reduces their quality of life and can lead to poor compliance with treatment. ... Huntington’s disease.
Wave’s challenge to Sarepta in Duchenne falls flat

The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD. ... Another drug candidate derived from that platform – WVE-120102 for Huntington’s disease – is in a phase 1b/2a trial (PRECISION-HD2)
Alkermes boosts CNS presence with $950m Rodin acquisition

The deal will see Alkermes expand its reach into central nervous system (CNS) diseases, by gaining a portfolio of pre-clinical assets for Alzheimer’s disease, Huntington’s disease, frontotemporal dementia ... Rodin's targeted approach to
Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst

The $845m deal focused mainly on central nervous system diseases, and was formed in 2015 with a Parkinson’s disease candidate the lead project. ... Sanofi handed back rights to that two years ago, and has now done the same with gene therapies for
UniQure gets speedy US review for Huntington’s gene therapy

vector carrying gene designed to reduce levels of an overexpressed protein in Huntington’s disease. ... Matt Kapusta. “Achieving fast track designation from the FDA underscores the high unmet medical need for patients suffering from Huntington’s

More from news
Approximately 6 fully matching, plus 40 partially matching documents found.

Latest Intelligence

Bluebird: on a mission to ‘recode’ the DNA of healthcare

to learn from its own mistakes with therapies for Huntington’s disease and also haemophilia. ... Increasingly factored into this equation is competition from companies following Bluebird into beta thalassemia and sickle cell disease.
Brain power: fresh approaches to Alzheimer’s drug discovery

Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as
Deal Watch October 2018

Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to
The European Medicines Agency: PRIME’d for access?

RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease. ... It’s hoped it could be a big step in treatment for the genetically-inherited and rare wasting disease.
Deal Watch May 2016

Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... disease late last year, Bayer announced another gene editing pact this month with ERS Genomics.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

uniQure appoints chief executive officer

This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Use of biomarkers in marketing

pathway. . When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’s disease and Alzheimer’s; these are prognosis biomarkers. ... A crowded market of biologics treating a chronic disease with very

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.